A Phase I, Open, Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs JS 001 (Primary)
- Indications Malignant melanoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 06 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 27 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History